The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial
Abstract
Background Conventional anticoagulant treatment for acute deep vein thrombosis (DVT) effectively prevents thrombus extension and recurrence, but does not dissolve the clot, and many patients develop post-thrombotic syndrome (PTS). We aimed to examine whether additional treatment with catheter-directed thrombolysis (CDT) using alteplase reduced development of PTS.Methods Participants in this open-label, randomised controlled trial were recruited from 20 hospitals in the Norwegian southeastern health region. Patients aged 18-75 years with a first-time iliofemoral DVT were included within 21 days from symptom onset. Patients were randomly assigned (1:1) by picking lowest number of sealed envelopes to conventional treatment alone or additional CDT. Randomisation was stratified for involvement of the pelvic veins with blocks of six. We assessed two co-primary outcomes: frequency of PTS as assessed by Villalta score at 24 months, and iliofemoral patency after 6 months. Analyses were by intention to treat. This trial is registered at ClinicalTrials.gov, NCT00251771.Findings 209 patients were randomly assigned to treatment groups (108 control, 101 CDT). At completion of 24 months' follow-up, data for clinical status were available for 189 patients (90%; 99 control, 90 CDT). At 24 months, 37 (41·1%, 95% CI 31·5-51·4) patients allocated additional CDT presented with PTS compared with 55 (55·6%, 95% CI 45·7-65·0) in the control group (p=0·047). The difference in PTS corresponds to an absolute risk reduction of 14·4% (95% CI 0·2-27·9), and the number needed to treat was 7 (95% CI 4-502). Iliofemoral patency after 6 months was reported in 58 patients (65·9%, 95% CI 55·5-75·0) on CDT versus 45 (47·4%, 37·6-57·3) on control (p=0·012). 20 bleeding complications related to CDT included three major and five clinically relevant bleeds.Interpretation Additional CDT should be considered in patients with a high proximal DVT and low risk of bleeding.Funding South-Eastern Norway Regional Health Authority; Research Council of Norway; University of Oslo; Oslo University Hospital.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general, thrombolytics were systemically infused, except in 4 trials, including the recently published ATTRACT trial, in which thrombolytics were catheter directed 133,134,146,148 and 2 trials in which thrombolytics were locoregionally infused. 141,142”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [134]
Citations
Cites
The Epidemiology of Venous Thromboembolism
White, R. H. (2003) · Circulation · doi:10.1161/01.cir.0000078468.11849.66 · Cited by 2,310
What is meant by intention to treat analysis? Survey of published randomised controlled trials
Hollis, S., & Campbell, F. (1999) · BMJ · doi:10.1136/bmj.319.7211.670 · Cited by 2,160
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Natural History of Venous Thromboembolism
Kearon, C. (2003) · Circulation · doi:10.1161/01.cir.0000078464.82671.78 · Cited by 1,048
Mewissen, M. W., Seabrook, G. R., Meissner, M. H., Cynamon, J., Labropoulos, N., & Haughton, S. H. (1999) · Radiology · doi:10.1148/radiology.211.1.r99ap4739 · Cited by 905
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa035451 · Cited by 887
Brandjes, D. P., Büller, H. R., Heijboer, H., Huisman, M. V., de Rijk, M., Jagt, H., & ten Cate, J. W. (1997) · The Lancet · doi:10.1016/s0140-6736(96)12215-7 · Cited by 873
Determinants and Time Course of the Postthrombotic Syndrome after Acute Deep Venous Thrombosis
Kahn, S. R., Shrier, I., Julian, J. A., Ducruet, T., Arsenault, L., Miron, M.-J., Roussin, A., Desmarais, S., Joyal, F., Kassis, J., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-10-200811180-00004 · Cited by 854
Prandoni, P., Lensing, A. W. A., Prins, M. H., Frulla, M., Marchiori, A., Bernardi, E., Tormene, D., Mosena, L., Pagnan, A., & Girolami, A. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-4-200408170-00004 · Cited by 659
Kahn, S. R., Partsch, H., Vedantham, S., Prandoni, P., & Kearon, C. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03294.x · Cited by 513
Research works printed but not linked: 1
- Villalta, 1994, Assessment of validity and reproducibility of a clinical scale for the postthrombotic syndrome, Haemostasis, 24, 157
Cited by
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
Antithrombotic Therapy for VTE Disease
Stevens, S. M., Woller, S. C., Kreuziger, L. B., Bounameaux, H., Doerschug, K., Geersing, G.-J., Huisman, M. V., Kearon, C., King, C. S., Knighton, A. J., et al. (2021) · Chest · doi:10.1016/j.chest.2021.07.055 · Cited by 1,043
Deep vein thrombosis and pulmonary embolism
Di Nisio, M., van Es, N., & Büller, H. R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30514-1 · Cited by 994
Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis
Vedantham, S., Goldhaber, S. Z., Julian, J. A., Kahn, S. R., Jaff, M. R., Cohen, D. J., Magnuson, E., Razavi, M. K., Comerota, A. J., Gornik, H. L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615066 · Cited by 866
Metadata
- Authors
- Enden, T., Haig, Y., Kløw, N.-E., Slagsvold, C.-E., Sandvik, L., Ghanima, W., Hafsahl, G., Holme, P. A., Holmen, L. O., Njaastad, A. M., Sandbæk, G., & Sandset, P. M.
- Affiliations
- Oslo University Hospital (NO)
- Østfold Hospital Trust (NO)
- Corresponding author
- Sandset, Per Morten
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 379
- Issue
- 9810
- Pages
- 31-38
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2103286082
- Cited by
- 990
- References
- 35
- Citations by year
- 2026: 42 · 2025: 50 · 2024: 80 · 2023: 58 · 2022: 59 · 2021: 83 · 2020: 78 · 2019: 65 · 2018: 80 · 2017: 80 · 2016: 73 · 2015: 75 · 2014: 72 · 2013: 62 · 2012: 28
- FWCI
- 45.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Universitetet i Oslo
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Clinical Neurology › Cerebral Venous Sinus Thrombosis
- Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
- Keywords
- catheter-directed thrombolysis, alteplase, post-thrombotic syndrome, anticoagulation, bleeding complications, long-term outcomes, venous thromboembolism, Villalta score, number needed to treat, risk mitigation
- MeSH terms
- Acute Disease, Anticoagulants, Catheterization, Peripheral, Female, Femoral Vein, Humans, Iliac Vein, Male, Middle Aged, Thrombolytic Therapy, Treatment Outcome, Venous Thrombosis, Postthrombotic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(11)61753-4
- The paper
- Enden, T., Haig, Y., Kløw, N.-E., Slagsvold, C.-E., Sandvik, L., Ghanima, W., Hafsahl, G., Holme, P. A., Holmen, L. O., Njaastad, A. M., Sandbæk, G., & Sandset, P. M. (2012). Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(11)61753-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.